INIS
patients
100%
heart failure
88%
fluids
75%
data
41%
therapy
37%
cost
37%
evaluation
37%
trajectories
37%
validation
37%
assessments
37%
intake
37%
clinical trials
37%
symptoms
19%
risks
12%
mortality
10%
males
8%
reliability
8%
cities
6%
safety
6%
kansas
6%
medical centers
6%
universities
6%
diseases
5%
hypertrophy
5%
surges
5%
morbidity
5%
chains
5%
hospitals
5%
Keyphrases
Heart Failure Patients
40%
Comprehensive Evaluation
37%
Cardiac Resynchronization Therapy
37%
Care Pathway
37%
Transthyretin Amyloidosis
37%
Transthyretin Amyloid Cardiomyopathy
37%
Diagnostic Trajectory
37%
Maastricht
37%
Fluid Status
37%
Status Assessment
37%
Fluid Intake
37%
Randomized Clinical Trial
37%
Liberal Fluid
37%
Chronic Heart Failure
37%
Fluid Restriction
37%
Confidence Interval
11%
Thirst Distress
10%
Safety Events
10%
Kansas City Cardiomyopathy Questionnaire
10%
Usual Care
7%
Time to Referral
6%
ATTRwt
6%
Red Flags
6%
E-health
6%
Risk Model
6%
University Medical Centre
5%
Maastricht University
5%
Baseline Scores
5%
Health Status
5%
Open-label Trial
5%
Patients with Chronic Heart Failure
5%
All-cause Mortality
5%
Nurse-led
5%
Heart Failure Hospitalization
5%
Medicine and Dentistry
Congestive Heart Failure
48%
Care Pathway
37%
Health Care Cost
37%
Cardiac Resynchronization Therapy
37%
Transthyretin
37%
Heart Amyloidosis
37%
Randomized Clinical Trial
37%
Awareness
34%
Amyloid Cardiomyopathy
34%
Myocardial Disease
18%
Thirst
18%
Open-Label Trial
9%
Health Status
9%
Outpatient
9%
Patient Referral
6%
Cardiovascular System
5%
Cost-Effectiveness Analysis
5%
All Cause Mortality
5%
Nurse
5%